LGALS9 and cancer: In spite of the significantly prognostic differences in the subgroups of Gal-9 on TILs in combination with PD-L1 on cancer cells (p=0.046) or FOXP3 (p=0.014), the double immune biomarkers positive group failed to fully reflect the objective fact for its limited sample size.